Microbot Medical ( (MBOT)) has issued an announcement. On November 5, 2025, Microbot Medical announced the limited commercial availability of its LIBERTY® Endovascular Robotic System in the U.S. This ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
Fintel reports that on October 15, 2025, HC Wainwright & Co. reiterated coverage of Microbot Medical (NasdaqCM:MBOT) with a Buy recommendation. Analyst Price Forecast Suggests 325.00% Upside As of ...
About 11 schools in Aurora receive robotics kits from the Department of Science and Technology, providing students with hands-on exposure to science, technology, engineering, and mathematics. (DOST) ...
THE Department of Science and Technology (DOST) distributed robotics kits amounting to P4.8 million to provide students in 11 schools in Aurora with hands-on exposure to science, technology, ...
MBOT’s main value driver is its LIBERTY robot. This is a disposable, portable endovascular robot that has great potential. LIBERTY showed strong ACCESS-PVI data and now awaits FDA 510(k) clearance for ...
Microbot Medical Inc. (MBOT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...
HINGHAM, Mass. - Microbot Medical Inc. (NASDAQ:MBOT), a developer of the LIBERTY Endovascular Robotic System, is actively preparing for the system’s anticipated U.S. launch projected for the third ...
HINGHAM, Mass. - Microbot Medical Inc. (NASDAQ:MBOT), a developer of the LIBERTY Endovascular Robotic System and currently valued at $71.23 million, has announced the appointment of two new senior ...
We recently published a list of the 10 Best Rising Penny Stocks to Buy According to Analysts. In this article, we are going to take a look at where Microbot Medical Inc. (NASDAQ:MBOT) stands against ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.